Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07124351 · ClinicalTrials.gov registry record · Phase 4
Intraoperative Imaging of Gastrointestinal Malignancies Using Pafolacianine (CYTALUX™)
A Phase 4 study of Gastric Cancer and Esophageal Cancer, sponsored by Cedars-Sinai Medical Center.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT07124351 is a Phase 4 study of Gastric Cancer and Esophageal Cancer that is actively recruiting participants, run by Cedars-Sinai Medical Center. The registered enrollment target is 15 participants, below the 319-participant average among 153 other Gastric Cancer trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07124351, a Phase 4 study of Gastric Cancer and Esophageal Cancer, is actively recruiting participants, sponsored by Cedars-Sinai Medical Center.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an open-label study in adults to determine feasibility of using CYTALUX™ (pafolacianine) injection with near-infrared (NIR) fluorescent imaging for detecting any type adenocarcinoma (gastric, esophageal and appendiceal).
Conditions Studied
Interventions
- DRUG CYTALUX™ (pafolacianine)
Study Locations (1)
California
- Cedars-Sinai Medical Center - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2025-09-05 |
| Est. Completion | 2026-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07124351
The ClinicalTrials.gov registry entry for NCT07124351 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 319-participant average among 153 other Gastric Cancer trials with a reported enrollment target (95% lower). The listed sponsor is Cedars-Sinai Medical Center, which has 339 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Gastric Cancer appearing as the primary indexed condition, and to 1 intervention - of which CYTALUX™ (pafolacianine) is the first listed.
NCT07124351 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT07124351 about?
NCT07124351 is a clinical study titled "Intraoperative Imaging of Gastrointestinal Malignancies Using Pafolacianine (CYTALUX™)". This is an open-label study in adults to determine feasibility of using CYTALUX™ (pafolacianine) injection with near-infrared (NIR) fluorescent imaging for detecting any type adenocarcinoma (gastric, esophageal and appendiceal).
What is the current status of trial NCT07124351?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 15 participants. The study started on 2025-09-05. Estimated completion is 2026-09.
What conditions does trial NCT07124351 study?
This clinical trial studies the following conditions: Gastric Cancer, Esophageal Cancer, Gastrointestinal Cancer, Appendiceal Cancer.
What interventions are being tested in trial NCT07124351?
The interventions under investigation include: CYTALUX™ (pafolacianine) (DRUG).
Who is sponsoring clinical trial NCT07124351?
This trial is sponsored by Cedars-Sinai Medical Center, which has 339 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07124351 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastric Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Helicobacter Pylori Screening and Treatment in the At-risk South Florida Community-AIM 2
ACTIVE NOT RECRUITING · Phase 4
-
Helicobacter Pylori Screening and Treatment in the At-risk South Florida Community- AIM 1
ACTIVE NOT RECRUITING · Phase 4
-
Improving Complete Endoscopic Mucosal Resection (EMR) of Colorectal Neoplasia
COMPLETED · Phase 4
-
CONFIRM: Magnetic Resonance Guided Radiation Therapy
RECRUITING · NA
-
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
RECRUITING · Phase 1
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.